Interactions of Glucose Metabolism and Chronic Heart Failure

Abstract

Background: We evaluated insulin sensitivity and beta cell function in patients with chronic heart failure (CHF), and investigated a possible correlation of these metabolic parameters with specific biomarkers of heart failure. Additionally, we investigated the effects of two angiotensin receptor blockers (ARBs), namely telmisartan and candesartan, that were administered over a 5 month treatment period, as additional therapy to standard care.

Methods and Results: The study group consisted of 94 CHF patients. Insulin sensitivity (OGIS index) and insulin secretion parameters were investigated by frequently sampled oral glucose tolerance tests and consecutive mathematical modelling. In total, 94.6 % of patients had clinically overt diabetes, impaired glucose tolerance or insulin resistance at the time of enrolment HbA1c was found to correlate to NT-proBNP, MR-proADM, CT-proET-1, and MR-proANP, but not to Copeptin. NT-proBNP correlated inversely to OGIS. None of the metabolic parameters were altered significantly after candesartan or telmisartan treatment in either the patient or standard care group.

Conclusion: Insulin sensitivity and insulin secretion are impaired in CHF and biomarkers of heart failure and atherosclerotic disease correlate to glucose metabolism.

Key words

cardiovascular incidences - metabolic features - obesity

References

• 1 Bobbio M, Ferrua S, Opasich C, Porcu M, Lucci D, Scherillo M, Tavazzi L, Maggioni AP. Survival and hospitalization in heart failure patients with or without diabetes treated with beta-blockers.  J Card Fail. 2003;  9 ((3)) 192-202
• 2 Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D. Diabetic neuropathies: a statement by the American Diabetes Association.  Diabetes Care. 2005;  28 ((4)) 956-962
• 3 Chi Lim S, Morgenthaler NG, Subramaniam T, Wu YS, Goh SK, Sum CF. The relationship between adrenomedullin, metabolic factors and vascular function in individuals with type 2 diabetes mellitus.  Diabetes Care. 2007; 
• 4 Chow LT, Chow SS, Anderson RH, Gosling JA. Autonomic innervation of the human cardiac conduction system: changes from infancy to senility–an immunohistochemical and histochemical analysis.  Anat Rec. 2001;  264 ((2)) 169-182
• 5 Diamantopoulos EJ, Andreadis EA, Tsourous GI, Ifanti GK, Katsanou PM, Georgiopoulos DX, Vassilopoulos CV, Dimitriadis G, Raptis SA. Metabolic syndrome and prediabetes identify overlapping but not identical populations.  Exp Clin Endocrinol Diabetes. 2006;  114 ((7)) 377-383
• 6 Doehner W, Rauchhaus M, Godsland IF, Egerer K, Niebauer J, Sharma R, Cicoira M, Florea VG, Coats AJ, Anker SD. Insulin resistance in moderate chronic heart failure is related to hyperleptinaemia, but not to norepinephrine or TNF-alpha.  Int J Cardiol. 2002;  83 ((1)) 73-81
• 7 Gegenhuber A, Struck J, Dieplinger B, Poelz W, Pacher R, Morgenthaler NG, Bergmann A, Haltmayer M, Mueller T. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure.  J Card Fail. 2007;  13 ((1)) 42-49
• 8 Gegenhuber A, Struck J, Poelz W, Pacher R, Morgenthaler NG, Bergmann A, Haltmayer M, Mueller T. Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B-type natriuretic pep-tide (BNP) and amino-terminal proBNP.  Clin Chem. 2006;  52 ((5)) 827-831
• 9 Hambrecht R, Fiehn E, Yu J, Niebauer J, Weigl C, Hilbrich L, Adams V, Riede U, Schuler G. Effects of endurance training on mitochondrial ultrastructure and fiber type distribution in skeletal muscle of patients with stable chronic heart failure.  J Am Coll Cardiol. 1997;  29 ((5)) 1067-1073
• 10 Hambrecht R, Niebauer J, Fiehn E, Kalberer B, Offner B, Hauer K, Riede U, Schlierf G, Kubler W, Schuler G. Physical training in patients with stable chronic heart failure: effects on cardiorespiratory fitness and ultrastructural abnormalities of leg muscles.  J Am Coll Cardiol. 1995;  25 ((6)) 1239-1249
• 11 Hayashi M, Shimosawa T, Fujita T. Hyperglycemia increases vascular adrenomedullin expression.  Biochem Biophys Res Commun. 1999;  258 ((2)) 453-456
• 12 Hickey MS, Weidner MD, Gavigan KE, Zheng D, Tyndall GL, Houmard JA. The insulin action-fiber type relationship in humans is muscle group specific.  Am J Physiol. 1995;  269 ((1 Pt 1)) E150-E154
• 13 Honjo S, Nichi Y, Wada Y, Hamamoto Y, Koshiyama H. Possible beneficial effect of telmisartan on glycemic control in diabetic subjects.  Diabetes Care. 2005;  28 ((2)) 498
• 14 Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance.  J Intern Med. 1999;  245 ((6)) 621-625
• 15 Hulsmann M, Berger R, Sturm B, Bojic A, Woloszczuk W, Bergler-Klein J, Pacher R. Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure.  Eur Heart J. 2002;  23 ((11)) 886-891
• 16 Katsuki A, Sumida Y, Gabazza EC, Murashima S, Urakawa H, Morioka K, Kitagawa N, Tanaka T, Araki-Sasaki R, Hori Y, Nakatani K, Yano Y, Adachi Y. Acute hyperinsulinemia is associated with increased circulating levels of adrenomedullin in patients with type 2 diabetes mellitus.  Eur J Endocrinol. 2002;  147 ((1)) 71-75
• 17 Katsuki A, Sumida Y, Urakawa H, Gabazza EC, Maruyama N, Morioka K, Kitagawa N, Hori Y, Nakatani K, Yano Y, Adachi Y. Increased oxidative stress is associated with elevated plasma levels of adrenomedullin in hypertensive patients with type 2 diabetes.  Diabetes Care. 2003;  26 ((5)) 1642-1643
• 18 Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.  J Clin Endocrinol Metab. 2000;  85 ((7)) 2402-2410
• 19 Khan SQ, Dhillon OS, RJ’Brien O, Struck J, Quinn PA, Morgenthaler NG, Squire IB, Davies JE, Bergmann A, Ng LL. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study.  Circulation. 2007;  115 ((16)) 2103-2110
• 20 Kinoshita H, Kato K, Kuroki M, Nakamura S, Kitamura K, Hisanaga S, Fujimoto S, Eto T. Plasma adrenomedullin levels in patients with diabetes.  Diabetes Care. 2000;  23 ((2)) 253-254
• 21 Korosoglou G, Humpert PM. Non-invasive diagnostic imaging techniques as a window into the diabetic heart: a review of experimen-tal and clinical data.  Exp Clin Endocrinol Diabetes. 2007;  115 ((4)) 211-220
• 22 Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JN. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure.  Am J Cardiol. 1982;  49 ((7)) 1659-1666
• 23 Lillioja S, Young AA, Culter CL, Ivy JL, Abbott WG, Zawadzki JK, Yki-Jarvinen H, Christin L, Secomb TW, Bogardus C. Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man.  J Clin Invest. 1987;  80 ((2)) 415-424
• 24 Linnemann B, Voigt W, Nobel W, Janka HU. C-reactive protein is a strong independent predictor of death in type 2 diabetes: association with multiple facets of the metabolic syndrome.  Exp Clin Endocrinol Diabetes. 2006;  114 ((3)) 127-134
• 25 Marangou AG, Alford FP, Ward G, Liskaser F, Aitken PM, Weber KM, Boston RC, Best JD. Hormonal effects of norepinephrine on acute glucose disposal in humans: a minimal model analysis.  Metabolism. 1988;  37 ((9)) 885-891
• 26 Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test.  Diabetes Care. 2001;  24 ((3)) 539-548
• 27 Martin S, Schramm W, Schneider B, Neeser K, Weber C, Lodwig V, Heinemann L, Scherbaum WA, Kolb H. Epidemiology of complications and total treatment costs from diagnosis of type 2 diabetes in Germany (ROSSO 4).  Exp Clin Endocrinol Diabetes. 2007;  115 ((8)) 495-501
• 28 Massie B, Conway M, Yonge R, Frostick S, Ledingham J, Sleight P, Radda G, Rajagopalan B. Skeletal muscle metabolism in patients with congestive heart failure: relation to clinical severity and blood flow.  Circulation. 1987;  76 ((5)) 1009-1019
• 29 Michel MC, Bohner H, Koster J, Schafers R, Heemann U. Safety of telmisartan in patients with arterial hypertension : an open-label observational study.  Drug Saf. 2004;  27 ((5)) 335-344
• 30 Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States.  Jama. 2001;  286 ((10)) 1195-1200
• 31 Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay.  Clin Chem. 2005;  51 ((10)) 1823-1829
• 32 Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin.  Clin Chem. 2006;  52 ((1)) 112-119
• 33 Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma.  Clin Chem. 2004;  50 ((1)) 234-236
• 34 Pacher R, Stanek B, Hulsmann M, Koller-Strametz J, Berger R, Schuller M, Hartter E, Ogris E, Frey B, Heinz G, Maurer G. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure.  J Am Coll Cardiol. 1996;  27 ((3)) 633-641
• 35 Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function.  Best Pract Res Clin Endocrinol Metab. 2003;  17 ((3)) 305-322
• 36 Paolisso G, Riu S De, Marrazzo G, Verza M, Varricchio M, D’Onofrio F. Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure.  Metabolism. 1991;  40 ((9)) 972-977
• 37 Papassotiriou J, Morgenthaler NG, Struck J, Alonso C, Bergmann A. Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma.  Clin Chem. 2006;  52 ((6)) 1144-1151
• 38 Pershadsingh HA. Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis?.  Expert Opin Investig Drugs. 2004;  13 ((3)) 215-228
• 39 Pollare T, Lithell H, Selinus I, Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension.  Diabetologia. 1988;  31 ((7)) 415-420
• 40 Sainaghi PP, Castello L, Bergamasco L, Carnevale Schianca GP, Bartoli E. Metabolic characteristics of glucose intolerance: the critical role of obesity.  Exp Clin Endocrinol Diabetes. 2008;  116 ((2)) 86-93
• 41 Schwarz PE, Reimann M, Li J, Bergmann A, Licinio J, Wong ML, Bornstein SR. The Metabolic Syndrome – a global challenge for prevention.  Horm Metab Res. 2007;  39 ((11)) 777-780
• 42 Stoiser B, Mortl D, Hulsmann M, Berger R, Struck J, Morgenthaler NG, Bergmann A, Pacher R. PacheCopeptin r, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure.  Eur J Clin Invest. 2006;  36 ((11)) 771-778
• 43 Struck J, Morgenthaler NG, Bergman A. Copeptin n, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients.  Peptides. 2005;  26 ((12)) 2500-2504
• 44 Sugo S, Minamino N, Shoji H, Kangawa K, Matsuo H. Effects of vasoactive substances and cAMP related compounds on adrenomedullin production in cultured vascular smooth muscle cells.  FEBS Lett. 1995;  369 ((2–3)) 311-314
• 45 Sullivan MJ, Knight JD, Higginbotham MB, Cobb FR. Relation between central and peripheral hemodynamics during exercise in patients with chronic heart failure. Muscle blood flow is reduced with maintenance of arterial perfusion pressure.  Circulation. 1989;  80 ((4)) 769-781
• 46 Suskin N, MacKelvie RS, Burns RJ, Latini R, Pericak D, Probstfield J, Rouleau JL, Sigouin C, Solymoss CB, Tsuyuki R, White M, Yusuf S. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure.  Eur Heart J. 2000;  21 ((16)) 1368-1375
• 47 Swan JW, Anker SD, Walton C, Godsland IF, Clark AL, Leyva F, Stevenson JC, Coats AJ. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure.  J Am Coll Cardiol. 1997;  30 ((2)) 527-532
• 48 Swan JW, Walton C, Godsland IF, Clark AL, Coats AJ, Oliver MF. Insulin resistance in chronic heart failure.  Eur Heart J. 1994;  15 ((11)) 1528-1532
• 49 Tanner H, Mohacsi P, Fuller-Bicer GA, Rieben R, Meier B, Hess O, Hullin R. Cytokine activation and disease progression in patients with stable moderate chronic heart failure.  J Heart Lung Transplant. 2007;  26 ((6)) 622-629
• 50 Torre-Amione G. Immune activation in chronic heart failure.  Am J Cardiol. 2005;  95 ((11A)) 3C-8C , ; discussion 38C–40C
• 51 Tsutamoto T, Horie M. Brain natriuretic peptide.  Rinsho Byori. 2004;  52 ((8)) 655-668
• 52 Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, Ohnishi M, Sugimoto Y, Kinoshita M. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction.  Circulation. 1997;  96 ((2)) 509-516
• 53 Tura A, Kautzky-Willer A, Pacini G. Insulinogenic indices from insulin and C-peptide: comparison of beta-cell function from OGTT and IVGTT.  Diabetes Res Clin Pract. 2006;  72 ((3)) 298-301
• 54 Turk HM, Buyukberber S, Sevinc A, Ak G, Ates M, Sari R, Savli H, Cigli A. Relationship between plasma adrenomedullin levels and metabolic control, risk factors, and diabetic microangiopathy in patients with type 2 diabetes.  Diabetes Care. 2000;  23 ((6)) 864-867
• 55 Usui I, Fujisaka S, Yamazaki K, Takano A, Murakami S, Yamazaki Y, Urakaze M, Hachiya H, Takata M, Senda S, Iwata M, Satoh A, Sasaoka T, Ak ND, Temaru R, Kobayashi M. Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients.  Diabetes Res Clin Pract. 2007; 
• 56 Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).  Circulation. 2003;  107 ((9)) 1291-1296
• 57 Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy.  Circulation. 2007;  115 ((3)) 387-397
• 58 Vitale C, Mercuro G, Castiglioni C, Cornoldi A, Tulli A, Fini M, Volterrani M, Rosano GM. Metabolic effect of telmisartan and losartan in hyper-tensive patients with metabolic syndrome.  Cardiovasc Diabetol. 2005;  4 6
• 59 Wilson JR, Martin JL, Schwartz D, Ferraro N. Exercise intolerance in patients with chronic heart failure: role of impaired nutritive flow to skeletal muscle.  Circulation. 1984;  69 ((6)) 1079-1087
• 60 Zabetian AHF, Azizi F. Relationship between metabolic syndrome and its components with coronary heart disease in Iranian men and women.  Experimental and Clinical Endocrinology & Diabetes. 2008;  , eFirst

Correspondence